Ascletis Pharma Eulerpool Vijesti

Ascletis Pharma Eulerpool News

Ascletis Pharma Aktie News

Ascletis Pharma prate mnogi novinari i investitori širom svijeta. Najnovije Ascletis Pharma vijesti prikupljamo ovdje.

• 17. rujna ·

  Yahoo
  Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity
• 31. srpnja ·

  SeekingAlpha
  Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide
• 11. lipnja ·

  Yahoo
  Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024
• 3. travnja ·

  Yahoo
  Ascletis Announces Strategic Decisions on FXR agonist ASC42
• 11. ožujka ·

  Yahoo
  Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
• 28. siječnja ·

  SeekingAlpha
  Week In Review: Arrivent BioPharma Raises $175M In IPO For In-Licensings From China
• 24. siječnja ·

  Yahoo
  Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
• 23. siječnja ·

  Yahoo
  Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
• 2. siječnja ·

  Yahoo
  Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis
• 5. prosinca ·

  Yahoo
  Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne